Global Human Albumin Market 2016-2020


◆タイトル:Global Human Albumin Market 2016-2020
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。





About the Human Albumin Market
Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer’s disease) are expected to enter the market during the forecast period.

The demand for albumin is high in APAC in countries like India and China. Still, the uptake of these therapeutics is less due to the lack of awareness about these products and their therapeutic uses. Thus, the awareness programs conducted by organizations such as PPTA, which includes International Plasma Awareness Week, to help increase the awareness about plasma donation and the different plasma protein therapies available, along with their potential uses, is expected to increase the uptake of these therapeutics in treating various conditions.

Technavio’s analysts forecast the global human albumin market to grow at a CAGR of 4.97% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Human Albumin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• CSL Behring
• Grifols
• Baxalta
• Octapharma
• Kedrion

[Other prominent vendors]
• AADi
• Ablynx
• Albumedix
• Ampio Pharmaceuticals
• Azaya Therapeutics
• Beijing Tiantan
• Biotest
• Bristol-Myers Squibb
• Celgene
• ConjuChem
• Hebei Changshan Biochem Pharma
• HiMedia Laboratories
• Hualan Biological Engineering
• InVittria
• MedxBio
• Merck
• Mitsubishi Tanabe Pharma
• NantBioScience
• Novo Nordisk
• Novozymes
• Shanghai RAAS Blood Products
• Sucampo Pharmaceuticals
• Teva Pharmaceuticals
• Thermo Fisher Scientific
• Tianjin SinoBiotech & Beijing Bio-Fortune
• Ventria Bioscience
• Yoshitomi Pharmaceutical

[Market driver]
• High demand for human albumin in China
• For a full, detailed list, view our report

[Market challenge]
• Spread of pathogenic contaminants
• For a full, detailed list, view our report

[Market trend]
• Rise in non-therapeutic applications
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Plasma therapeutics: An overview
• Components of blood plasma
• Derivation of various plasma therapeutics

PART 06: Global plasma therapeutics market
• Market overview
• Market size and forecast

PART 07: Plasma fractionation market
• Overview
• Market size and forecast
• Market players

PART 08: Albumin: An overview
• Types of albumin
• Albumin in human body
• Clinical uses

PART 09: Pipeline portfolio

PART 10: Global albumin market

PART 11: Market landscape
• Global human albumin market
• Five forces analysis

PART 12: Market segmentation by application
• Replacement therapy
• Drug formulation and delivery
• Vaccine ingredients
• Others

PART 13: Geographical segmentation
• Global human albumin market by geographical segmentation 2015-2020
• Human albumin market in APAC
• Human albumin market in Americas
• Human albumin market in EMEA

PART 14: China albumin market
• Plasma therapeutics market in China
• Human albumin market in China

PART 15: Market drivers
• High demand for human albumin in China
• Exploitation of new therapeutic indications
• Increase in production capacity

PART 16: Impact of drivers

PART 17: Market challenges
• High cost of therapy
• Spread of pathogenic contaminants
• High regulations in the market

PART 18: Impact of drivers and challenges

PART 19: Market trends
• Novel technologies for albumin-based drug development
• Rise in non-therapeutic applications
• Increased development of recombinant albumin

PART 20: Vendor landscape
• Competitive scenario
• Market analysis 2015
• CSL Behring
• Grifols
• Baxalta
• Octapharma
• Kedrion
• Other prominent vendors

PART 21: Appendix
• List of abbreviations

PART 22: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Blood plasma composition
Exhibit 03: Plasma proteins composition by percentage share
Exhibit 04: Total number of plasma donations in US 2010-2014
Exhibit 05: Projected global YoY growth and fractionation capacity of manufacturing units (millions of liter/annum)
Exhibit 06: Process of derivation of AAT from plasma
Exhibit 07: Global plasma therapeutics market 2015-2020 ($ billions)
Exhibit 08: Segmentation of plasma-derived products on revenue 2015
Exhibit 09: Global plasma fractionation market 2015-2020 ($ billions)
Exhibit 10: Line of treatment of albumin in various diseases
Exhibit 11: Pipeline portfolio: Albumin-based therapeutics
Exhibit 12: Segmentation of global albumin market
Exhibit 13: Global human albumin market 2015-2020 ($ billions)
Exhibit 14: Global human albumin market 2015-2020 (tons)
Exhibit 15: Five forces analysis
Exhibit 16: Segmentation of human albumin market based on application
Exhibit 17: Segmentation of global human albumin market based on geography 2015
Exhibit 18: Human albumin market revenue by geography 2015-2020 ($ billions)
Exhibit 19: Human albumin market by geography 2015-2020
Exhibit 20: Human albumin market in APAC 2015-2020 ($ billions)
Exhibit 21: Albumin market in China in global albumin market 2015
Exhibit 22: Human albumin market in Americas 2015-2020 ($ billions)
Exhibit 23: Albumin market in US 2015
Exhibit 24: Human albumin market in EMEA 2015-2020 ($ millions)
Exhibit 25: Global human albumin market: YoY growth and revenue based on geography 2015-2020
Exhibit 26: Segmentation of various plasma products 2015
Exhibit 27: Plasma therapeutics market in China 2015-2020 ($ billions)
Exhibit 28: Human albumin market in China 2015-2020 ($ billions)
Exhibit 29: Domestic and imported albumin in China 2015
Exhibit 30: Impact of drivers
Exhibit 31: Impact of drivers and challenges
Exhibit 32: CSL Behring: Segmentation by revenue 2015
Exhibit 33: CSL Behring: YoY revenue and growth rate of albumin products 2013-2015 ($ millions)
Exhibit 34: CSL Behring: Key takeaways
Exhibit 35: Grifols: YoY growth rate and revenue of bioscience segment 2013-2015 ($ billions)
Exhibit 36: Grifols: Key takeaways
Exhibit 37: Baxalta: Segmentation by revenue 2015
Exhibit 38: Baxalta: YoY revenue comparison of Biotherapeutics segment 2013-2015 ($ millions)
Exhibit 39: Baxalta: Geographic segmentation of BioTherapeutics 2015
Exhibit 40: Baxalta: Key takeaways
Exhibit 41: Octapharma: Key takeaways
Exhibit 42: Kedrion: Key takeaways


CSL Behring, Grifols, Baxalta, Octapharma, Kedrion, AADi, Ablynx, Albumedix, Ampio Pharmaceuticals, Azaya Therapeutics, Beijing Tiantan, Biotest, Bristol-Myers Squibb, Celgene, ConjuChem, GSK, Hebei Changshan Biochem Pharma, HiMedia Laboratories, Hualan Biological Engineering, InVittria, MedxBio, Merck, Mitsubishi Tanabe Pharma, NantBioScience, Novo Nordisk, Novozymes, Shanghai RAAS Blood Products, Sucampo Pharmaceuticals, Teva Pharmaceuticals, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, Ventria Bioscience, Yoshitomi Pharmaceutical.


ヒトアルブミン、治療、医薬品、ワクチン、 ヒトアルブミン用途